Literature DB >> 24232856

Association between variants of the autophagy related gene--IRGM and susceptibility to Crohn's disease and ulcerative colitis: a meta-analysis.

Xiao Cheng Lu1, Yi Tao, Chen Wu, Peng Lai Zhao, Kai Li, Jin Yu Zheng, Li Xin Li.   

Abstract

BACKGROUND: Polymorphisms in immunity-related GTPase family M (IRGM) gene may be associated with inflammatory bowel disease (IBD) by affecting autophagy. However, the genetic association studies on three common variants in IRGM gene (rs13361189, rs4958847 and rs10065172) have shown inconsistent results. METHODOLOGY/ PRINCIPAL
FINDINGS: The PubMed and Embase were searched up to June 5, 2013 for studies on the association between three IRGM polymorphisms and IBD risk. Data were extracted and the odd ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. Finally, we performed a meta-analysis of 25 eligible studies in 3 SNPs located at IRGM gene by using a total of 20590 IBD cases and 27670 controls. The analysis showed modest significant association for the rs13361189, rs4958847 and rs10065172 variants in Crohn's disease (CD): the risk estimates for the allele contrast were OR=1.306 (1.200-1.420), p=5.2 × 10(-10), OR=1.182 (1.082-1.290), p=0.0002, and OR=1.248 (1.057-1.473), p=0.009 respectively (still significant when the p value was Bonferroni adjusted to 0.017). When stratified by ethnicity, significantly increased CD risk was observed in Europeans, but not in Asians. Conversely, there was no association of rs13361189 or rs4958847 variant with risk of ulcerative colitis (UC). CONCLUSIONS/ SIGNIFICANCE: These results indicated that autophagy gene-IRGM polymorphisms appear to confer susceptibility to CD but not UC, especially in Europeans. Our data may provide further understanding of the role of autophagy in the pathogenesis of CD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24232856      PMCID: PMC3827440          DOI: 10.1371/journal.pone.0080602

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Inflammatory bowel disease (IBD), a chronic inflammatory disease of the gastrointestinal tract, is usually classified into two clinical forms: Crohn’s disease (CD) and ulcerative colitis (UC) [1,2]. CD generally involves the ileum and colon, and it can affect any region of the intestine in a continuous manner. UC involves the rectum and may affect part of the colon or the entire colon, often uninterruptedly. The etiology of IBD most likely involves a complex interaction of genetic and environmental factors. Although the etiology remains poorly understood, epidemiologic and linkage studies suggest that genetic factors are implicated in the pathogenesis of IBD [3-9]. Recent progress in the genetics of IBD has advanced understanding of disease pathogenesis. GWAS meta-analysis identified 71, 47 and 163 susceptibility loci of CD, UC and IBD, respectively. These genes involved in intestinal barrier function (GNA12 and LAMB1), transcriptional regulation (NKX2-3 and IRF5) and immune response (IL23R and IL12B). Recently, studies in animal models and IBD patients suggested that autophagy related genes (ATG16L1 and IRGM) may play an important role in the pathogenesis of IBD[10-12]. The immunity-related GTPase family M (IRGM) gene, located on chromosome 5q33.1, encodes a GTP-binding protein that induces autophagy, which is involved in elimination of intracellular pathogens[13,14]. Association of three common polymorphisms in IRGM gene (rs13361189, rs4958847 and rs10065172) with IBD has been recently reported [12,15-18]. However, the genetic association studies that investigated the association between IBD and rs13361189, rs4958847 or rs10065172 variant have produced inconclusive results. For instance, an accumulating number of studies suggested a positive association between IRGM polymorphisms and CD susceptibility [12,18,19], which, nevertheless, could not be replicated in several studies [16,20,21]. This inconsistency may be due to studies with limited sample sizes, inadequate statistical power, or ethnic differences. Meta-analysis is a proper method to deal with these ambiguities and overcome the problem of small sample sizes and inadequate statistical power in different genetic studies. In the present study, we performed a meta-analysis of all eligible case control and cohort studies to clarify the associations between three common polymorphisms (rs13361189, rs4958847 and rs10065172) in the IRGM gene and IBD (CD or UC) susceptibility.

Materials and Methods

Identification and eligibility of relevant studies

Electronic searches in Medline, Embase, CNKI (China National Knowledge Infrastructure) and Chinese Biomedicine databases were performed using the following search terms: ‘Inflammatory Bowel Disease’ or ‘IBD’, ‘Crohn’s disease’ or ‘CD’, ‘ulcerative colitis’ or ‘UC’, ‘IRGM’, ‘polymorphism’ or ‘variant’, ‘rs13361189’, ‘rs4958847’ or ‘rs10065172’, and ‘single nucleotide polymorphism’ or ‘SNP’( the last search update was 5 June 2013). In addition, the reference lists of all retrieved articles were checked for additional potential studies. A study was included in the analysis if (1) reported the relationship between the polymorphisms of IRGM rs13361189, rs4958847 or rs10065172and the risk of IBD; (2) the genetic information of included studies was from unrelated populations (studies of which the design was not based on family data). Major reasons for exclusion of studies: (1) no control population; (2) studies that contained overlapping data; (3) comments, letters, review articles, or articles only with an abstract. Additionally, when a study reported the results on different subpopulations or panels, we treated them as separate studies in the meta-analysis.

Data extraction

The following data was extracted independently from each study by two authors: first author, journal, year of publication, country of origin, ethnicity of the individuals involved (Europeans, Asians, or Africans), genotype frequency, sex and mean age in cases and controls. Of the studies with the overlapping data of the same population resource, we selected the most recent ones with the largest number of participants. If the article did not provide sufficient genotype distribution, the corresponding author was contacted for the detailed data. In addition, disagreements were resolved by discussion between the two investigators.

Statistical analysis

The strength of the association between IRGM polymorphisms and CD or UC risk was evaluated by the odds ratios (ORs) with 95% confidence intervals (CIs). For the rs13361189 polymorphism, we examined the allelic effect of C (minor allele) versus T (common allele), and also examined the contrast of CC versus TT, CT versus TT, CC+CT versus TT (dominant model), as well as CC versus CT+TT (recessive model). Similar models were analyzed for the rs4958847 and rs10065172 polymorphisms. The association between rs10065172 and UC risk was not evaluated for the lack of sufficient data. The significance of the pooled OR was determined by the Z-test; and the P values were adjusted using Bonferroni correction by the number of compared SNPs. (P=0.05/3=0.017) In addition, for each genetic contrast, stratified analysis was performed according to ethnicity. The Hardy-Weinberg equilibrium (HWE) in the control group was assessed, and P<0.05 was considered as significant disequilibrium. The heterogeneity between studies was assessed by Chi-square based Q test [22] and I2 test. Heterogeneity was considered significant when P<0.10, and then the random effect model was applied for meta-analysis, otherwise, a fixed-effects model was used [23]. I2 takes values between 0% and 100% with higher values denoting a greater degree of heterogeneity [24]. In addition, a meta-regression model was performed to explore the possible heterogeneity among different kinds of studies. Cumulative meta-analyses were carried out for all three variants in association with CD and two variants (rs13361189 and rs4958847) with UC to evaluate the trend of the genetic risk effect (OR) of the allele contrast as evidence accumulating over time. To assess the stability of the results, sensitivity analysis was carried out after sequential removal of each study or by excluding those studies deviated from HWE. Publication bias was investigated using graphical evaluation of funnel plots. However, the funnel plot may be not considered strictly as a test of publication bias. Then, the Egger’s test was used to provide statistical evidence of funnel plot symmetry [25]. If significant publication bias was detected, ORs and 95% CIs would be adjusted by trim and fill methods. All statistical analyses were performed by STATA software (version 12).

Results

Main characteristics of eligible studies

The literature review identified 62 articles in PubMed, Embase, CNKI and Chinese Biomedicine databases that met the search criteria. The abstracts and full articles of the retrieved studies were read to assess their appropriateness for meta-analysis. Finally, a total of 23 relevant articles with IRGM polymorphisms (rs13361189, rs4958857 or rs10065172) and IBD (UC or CD) were included in this meta-analysis. Figure 1 showed a flow chart of the retrieved studies and the excluded studies. Among them, one publication [16] contained data on two different subpopulations, one [18] included Wellcome Trust Case Control Consortium (WTCCC) samples and replication Crohn's disease (RCD) samples and we treated them independently. Therefore, 25 studies that comprised a total of 20590 IBD cases and 27670 controls were considered in our meta-analysis.
Figure 1

Flowchart of search strategy for meta-analysis.

A list of details of the studies included in the meta-analysis was provided in Table 1. The studies were published from 2007 to 2013. Studies were conducted in various populations of ethnic descent: 17 Europeans [12,15-19,21,26-35], 4 Asians [36-39], 1 Africans [20] and 1 Jewishs [40]. Because of the insufficient samples available for African and Jewish groups, we have performed subgroup analysis in Europeans and Asians. Although the allele frequency of the IRGM polymorphisms was extracted from 25 studies, 4 studies [19,28,30,31] did not include genotype distributions, but one [19] was included after we contacted the authors directly, who provided sufficient data. In 2 studies [18,21], the distribution of the genotypes in control group was not in HWE (P<0.05). Then, a sensitivity analysis was performed by excluding these studies from the analysis.
Table 1

Characteristics of Studies Included in the Meta-analysis.

Cases
Controls
Author, Year of publication Ethnicity IRGM variant    Phenotype Studied   Number Males (%)   Age or Age at diagnosis Number    Males (%)    Age Matching
Wang, 2012Africanrs13361189CDCD:35434.237.4±14.3 and 26.7±12.9 at diagnosis35442.639.8±12.7nr
rs4958847
rs10065172
Meggyesi1, 2010Europeanrs13361189CD and UC separatelyCD: 456 UC: 274CD:53.6CD: 37.1±12.6 and 26.5±10.6 at diagnosis271nrnrAge and sex
Meggyesi2, 2010Europeanrs13361189CD and UC separatelyCD:352 UC: 154UC:47.2UC: 43.7±15.0 and 31.3±13.4 at diagnosis198nrnr
Peter, 2011Jewishrs13361189CDCD:369nrnr503nrnrnr
Dema, 2009Europeanrs4958847CDCD:725nrnr956nrnrnr
rs10065172
Frank, 2008Europeanrs13361189CD and UC separatelyCD: 1850CD:32CD: 38 and 21 at diagnosis (median)1817nrnrAge and sex
rs4958847UC: 1103UC:42.8UC: 40 and 26 at diagnosis (median)
rs10065172
Wolfkamp, 2010Europeanrs13361189CDCD: 530nrnr529nrnrnr
rs4958847
Palomino-Morales,2009Europeanrs13361189CD and UC separatelyCD: 557nrnr672nrnrAge and sex
rs4958847UC: 425
Yamazaki, 2009Asianrs13361189CDCD: 48472.522.4(7–55)47050.238.7(21–77)nr
rs4958847
Prager, 2012Europeanrs13361189CD and UC separatelyCD: 464CD:37.5CD:29.5±11.6 at diagnosis5084260±16.2nr
rs4958847UC: 292UC:44.8UC:34.3±14.2 at diagnosis
Fisher, 2008Europeanrs13361189UCUC: 1841nrnr1470nrnrnr
rs4958847
Parkes (RCD), 2007Europeanrs13361189CDCD:118240.3CD: 43.9 and 25.5 at diagnosis (median)2024nrnrnr
rs4958847
Parkes (WTCCC), 2007Europeanrs13361189CDCD:174839.2CD: 45.7 and 26.1 at diagnosis (median)8655nrnrnr
rs4958847
Roberts, 2009Europeanrs13361189CD and UC separatelyCD: 507nrnr576nrnrnr
rs4958847UC: 475
Latiano, 2009Europeanrs4958847CD and UC separatelyCD: 823CD: 30 ± 15 at diagnosis578nrnrnr
UC: 353UC: 25 ± 16 at diagnosis
Zheng, 2012Asianrs13361189CDCD:31848.4CD: 37.2±11.431849.136.7±12.3nr
Prescott, 2010Europeanrs13361189CDCD:1848nrnr2025nrnrnr
rs10065172
Pang, 2011Asianrs13361189CDCD:6648.5CD:36.3±11.86650.035.4±13.1nr
Limbergen, 2009Europeanrs13361189CDCD:630nrnr3283nrnrnr
rs4958847
rs10065172
Weersma, 2009Europeanrs13361189CD and UC separatelyCD: 1656nrnr1086nrnrnr
rs4958847UC: 1075
Eglinton, 2012Europeanrs4958847CDCD: 50737.145±17.9507nrnrnr
Amre, 2009Europeanrs10065172CDCD: 28955.4CD: 12.1± 3.5 at diagnosis29052.411.4± 6.8nr
Duraes, 2013Europeanrs13361189CDCD: 51146.2CD: 28.6± 11.2 at diagnosis62638.530.5(9-83)sex
Glas, 2013Europeanrs13361189CD and UC separatelyCD: 817CD: 46.0CD: 40.7±13.3 and 27.9±12.0 at diagnosis96163.647.4±9.06nr
rs4958847UC: 283UC: 53.0UC: 43.8±14.4 and 31.3±13.7 at diagnosis
rs10065172
Moon, 2013Asianrs4958847CD and UC separatelyCD: 253CD:60.9CD:25.9±10.4 at diagnosis52056.539.3±15.8Age and sex
rs10065172UC: 257UC:50.6UC:37.1±12.4 at diagnosis

CD: Crohn’s disease, UC: ulcerative colitis, nr: not report.

CD: Crohn’s disease, UC: ulcerative colitis, nr: not report.

Quantitative synthesis

Crohn’s disease

The relevant studies included 38369 individuals (13043 cases and 25326 controls) for rs13361189 variant, 34397 individuals (10924 cases and 23473 controls) for rs4958847 variant, and 16972 individuals (6766 cases and 10206 controls) for rs10065172 variant. We observed a wide spectrum of the rs13361189 C allele and rs4958847 A allele frequencies across different ethnicities. Compared with Europeans controls (8.32%, 95% CI=7.07-9.58), Asian controls carried a higher frequency (35.37%, 95%CI= 31.13-39.60; p=2.5×10-13) of rs13361189 C allele. Similar result was observed in rs4958847 (p=1.8×10-10). For rs10065172 variant, as only one study carried out in Asians was included, one sample T-test was used to compare the differences of allele frequencies between Asian and European controls (p=9.9×10-7). (Figure 2)
Figure 2

Allele frequencies (%) in the three major ethnical groups in controls of CD to (A) rs13361189, (B) rs4958847 and (C) rs10065172.

Each data point represents a separate study for the indicated association. Horizontal line represents the mean value.

Allele frequencies (%) in the three major ethnical groups in controls of CD to (A) rs13361189, (B) rs4958847 and (C) rs10065172.

Each data point represents a separate study for the indicated association. Horizontal line represents the mean value. Table 2 showed the meta-analysis results of the association between the allele contrast and genetic models of the different gene polymorphisms and the risk of CD. Significantly elevated CD risk was associated with rs13361189, rs4958847 or rs10065172 for the allele contrast. (OR=1.306 (1.200-1.420), p=5.2×10-10, OR=1.182 (1.082-1.290), p=0.0002 and OR=1.248 (1.057-1.473), p=0.009 respectively, significant even after Bonferroni correction). Moreover, significant correlation was also found in the three polymorphisms under other genetic models (homozygote, heterozygote, dominant and recessive models). (Table 2, Figure 3)
Table 2

Pooled analysis for the associations between the polymorphism of IRGM and the risk of Crohn’s disease.

VariantComparisonVariablesData NO.Sameple Size
Test of association
ModelTest of heterogeneity
Case Control OR (95% CI) P-value I2 (%) P-value
rs13361189C vs TOverall1813043253261.306 (1.200-1.420)5.2×10-10*R55.50.002
Europeans1311806241181.396 (1.314-1.483)4.2×10-27*F35.20.101
Asians 38688541.084 (0.942-1.248)0.26F0.000.984
All in HWE159483113641.300(1.169-1.446)1.4×10-6*R62.50.001
CC vs TTOverall1712413220431.565 (1.218-2.010)0.0004*R38.70.053
Europeans1211176208352.042 (1.581-2.638)4.6×10-8*F11.10.336
Asians 38688541.064 (0.781-1.450)0.695F0.000.763
All in HWE159483113641.636 (1.220-2.193)0.001*R45.80.027
CT vs TTOverall1712413220431.360 (1.279-1.448)2.8×10-22*F27.80.138
Europeans1211176208351.390 (1.298-1.488)3.2×10-21*F21.50.232
Asians 38688541.239 (1.010-1.520)0.040F0.000.550
All in HWE159483113641.320 (1.198-1.454)1.9×10-8*R34.90.090
CC+CT vs TTOverall1712413220431.362 (1.255-1.479)1.3×10-13*R37.30.061
Europeans1211176208351.421 (1.329-1.519)5.0×10-25*F29.70.155
Asians 38688541.199 (0.987-1.455)0.068F0.000.816
All in HWE159483113641.345 (1.214-1.489)1.3×10-8*R44.60.032
CC vs CT+TTOverall1712413220431.448 (1.129-1.856)0.004*R41.50.038
Europeans1211176208351.919 (1.486-2.447)5.7×10-7*F9.400.353
Asians 38688540.941 (0.705-1.256)0.682F0.000.478
All in HWE159483113641.506 (1.128-2.012)0.006*R48.30.019
rs4958847A vs GOverall149854218921.182 (1.082-1.290)0.0002*R66.60.0002
Europeans119016210681.228 (1.117-1.349)0.00002*R64.00.002
Asians 27379701.062(0.925-1.220)0.395F33.60.220
All in HWE117578193981.195 (1.076-1.328)0.001*R72.10.00009
AA vs GGOverall139224186091.312 (1.045-1.647)0.019R55.70.008
Europeans108386177851.449 (1.084-1.936)0.012*R55.60.016
Asians 27379701.120 (0.844-1.485)0.434F24.20.251
All in HWE117578193981.373 (1.057-1.783)0.017R61.60.004
AG vs GGOverall139224186091.205 (1.097-1.323)0.0001*R51.20.017
Europeans108386177851.251 (1.138-1.376)3.8×10-6*R49.50.037
Asians 27379700.986 (0.766-1.268)0.911F0.000.426
All in HWE117578193981.192 (1.071-1.326)0.001*R54.60.015
AA+AG vs GGOverall139224186091.220 (1.106-1.347)0.00007*R59.10.004
Europeans108386177851.269 (1.147-1.403)3.6×10-6*R58.10.011
Asians 27379701.028 (0.810-1.304)0.820F12.90.284
All in HWE117578193981.216 (1.085-1.363)0.001*R63.40.002
AA vs AG+GGOverall139224186091.248 (1.028-1.515)0.025R48.70.025
Europeans108386177851.367 (1.037-1.802)0.026R51.70.028
Asians 27379701.132 (0.912-1.406)0.260F0.000.402
All in HWE117578193981.300 (1.043-1.619)0.019R55.10.014
rs10065172T vs COverall 8540784351.248 (1.057-1.473)0.009*R79.40.00002
Europeans 6505380811.284 (1.055-1.564)0.013R80.30.0001
TT vs CCOverall 7477751521.543 (1.078-2.207)0.018R48.90.068
Europeans 5442347981.717 (1.197-2.464)0.003*F12.60.334
TC vs CCOverall 7477751521.244 (1.012-1.530)0.038R78.30.0001
Europeans 5442347981.271 (0.988-1.636)0.062R83.20.00009
TT+TC vs CCOverall 7477751521.273 (1.030-1.573)0.025R80.60.00003
Europeans 5442347981.298 (1.008-1.673)0.043R84.10.00004
TT vs TC+CCOverall 7477751521.335 (1.078-1.653)0.008*F33.40.173
Europeans 5442347981.668 (1.162-2.393)0.006*F0.000.463

F: fixed-model; R: random model; *: P value significant even after Bonferroni correction by 3 comparisons (ie 3 compared SNPs, P=0.05/3=0.017); HWE: Hardy-Weinberg equilibrium.

Figure 3

OR estimates with the corresponding 95% CI for the associations between IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and the risk of CD (dominant model).

The sizes of the squares reflect the weighting of included studies; the centre of diamonds reflect summary effect, the left and right extremes of diamonds reflect 95% confidence intervals; CI, confidence interval; OR, odds ratio.

F: fixed-model; R: random model; *: P value significant even after Bonferroni correction by 3 comparisons (ie 3 compared SNPs, P=0.05/3=0.017); HWE: Hardy-Weinberg equilibrium.

OR estimates with the corresponding 95% CI for the associations between IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and the risk of CD (dominant model).

The sizes of the squares reflect the weighting of included studies; the centre of diamonds reflect summary effect, the left and right extremes of diamonds reflect 95% confidence intervals; CI, confidence interval; OR, odds ratio. In the subgroup analysis by ethnicity, for rs13361189 T>C, significantly increased CD risk was found among European populations in the allelic and all genetic models. (CC+CT vs TT: OR=1.421 (1.329-1.519), p=5.0×10-25, significant after Bonferroni correction) However, these associations were not observed in the Asian populations (CC+CT vs TT: OR=1.199 (0.987-1.455), p=0.068). Similarly, statistical association was observed between rs4958847 or rs10065172 variant and CD risk among European population. (AA+AG vs GG: OR=1.269 (1.147-1.403), p=3.6×10-6, still significant after Bonferroni correction) and TT+TC vs TT: OR=1.298 (1.008-1.673), p=0.043, non-significant after Bonferroni correction) In addition, the OR for rs13361189 T>C was 1.565 (1.218-2.010) in carriers of two risk C alleles compared with non-risk allele carriers (CC vs TT), which was higher than the risk of one T allele carriers (CT vs TT, OR= 1.360 (1.279-1.448)), suggesting a dose–response with increasing number of the variant allele. The same pattern was seen for either rs4958847 or rs10065172 variant.

Ulcerative colitis

Meta-analysis findings of associations between rs13361189 and rs4958847 in the IRGM gene and the risk of UC were shown in Table 3. A total of 4847 (5029) UC patients and 6473 (7202) controls for rs13361189 (rs4958847) polymorphism were investigated. No significant association was observed between the polymorphism of rs13361189 and the risk of UC in all comparisons (C vs T: OR=1.088 (0.989-1.198); p=0.083, CC vs TT: OR=1.428 (0.959-2.126), p=0.079; CT vs TT: OR=1.062 (0.955-1.180), p=0.266; dominant model: OR=1.079 (0.973-1.197), p=0.149; and recessive model: OR=1.395 (0.938-2.075), p=0.100.) (Figure S1) Similarly, for rs4955847 variant and UC risk, no obvious association was observed in allelic and genetic models. (Figure S1, Table 3)
Table 3

Pooled analysis for the associations between the polymorphisms of IRGM and the risk of ulcerative colitis.

VariantComparisonEthnicityData NO.Sample Size
Test of association
ModelTest of heterogeneity
Case Control OR (95% CI) P-value I2 P-value
rs13361189C vs TOverall (Europeans)8456455121.088 (0.989-1.198)0.083F0.000.462
CC vs TTOverall (Europeans)8456455121.428 (0.959-2.126)0.079F5.900.385
CT vs TTOverall (Europeans)8456455121.062 (0.955-1.180)0.266F0.000.459
CC+CT vs TTOverall (Europeans)8456455121.079 (0.973-1.197)0.149F0.000.456
CC vs CT+TTOverall (Europeans)8456455121.395 (0.938-2.075)0.100F7.600.372
rs4958847A vs GOverall 8448956211.031 (0.955-1.112)0.438F0.500.425
Europeans7423251011.023 (0.943-1.109)0.590F11.30.343
All in HWE7419751131.028 (0.950-1.112)0.491F13.90.324
AA vs GGOverall 8448956211.195 (0.937-1.525)0.151F0.000.863
Europeans7423251011.142 (0.860-1.518)0.359F0.000.821
All in HWE7419751131.250 (0.973-1.607)0.081F0.000.975
AG vs GGOverall8448956211.075 (0.921-1.254)0.361R59.90.015
Europeans7423251011.039 (0.894-1.208)0.621R56.70.031
All in HWE7419751131.057 (0.895-1.248)0.514R62.70.013
AA+AG vs GGOverall8448956211.066 (0.935-1.215)0.343R48.00.062
Europeans7423251011.015 (0.927-1.111)0.751F43.60.100
All in HWE7419751131.058 (0.916-1.222)0.446R53.60.044
AA vs AG+GGOverall8448956211.053 (0.852-1.302)0.631F0.000.747
Europeans7423251011.137 (0.857-1.508)0.375F0.000.727
All in HWE7419751131.086 (0.875-1.348)0.445F0.000.848

F: fixed-model; R: random model; HWE: Hardy-Weinberg equilibrium.

F: fixed-model; R: random model; HWE: Hardy-Weinberg equilibrium.

Test of heterogeneity

There was significant heterogeneity in most comparisons of three IRGM SNPs in the total analysis of CD. (Table 2) Then meta-regression was carried out to assess the source of heterogeneity for dominant model comparison by year of publication, ethnicity and sample size (individuals more than 500 in both cases and controls). The results showed that ethnicity could explain 41.37% and 19.77% of the τ2 in rs13361189 and rs4958847 variants, respectively. Moreover, sample size could explain 63.28% of τ2 under dominant model in rs13361189 variant. However, for rs10065172 variant, meta-regression analyses did not show any sources that contribute to the substantial heterogeneity.

Sensitivity analyses and cumulative meta-analysis

Sensitivity analyses indicated that the pooled ORs were consistently significant in CD by omitting one study at a time, suggesting robustness of our results. (Figure 4, Figure S2) Although there were two studies (18,21) which deviated from HWE, the corresponding pooled ORs were not materially altered with or without including these two studies in all comparisons. (Table 2, 3)
Figure 4

Sensitivity analysis on the associations between IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and CD risk (dominant model).

Results were computed by omitting each study (left column) in turn, Bars: 95% confidence interval.

Sensitivity analysis on the associations between IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and CD risk (dominant model).

Results were computed by omitting each study (left column) in turn, Bars: 95% confidence interval. In addition, sensitivity analyses showed that three independent studies [19,21,32] were the potential origin of heterogeneity in association between rs13361189 variant and CD risk. The heterogeneity was effectively removed by exclusion of these four studies (C vs T: Ph=0.121, CC vs TT: Ph=0.190, CT vs TT: Ph=0.700, CC+CT vs TT: Ph=0.595, and CC vs CT+TT: Ph=0.145). For rs4958847 variant, three studies [20,32,33] were responsible for the heterogeneity. The Q-test of heterogeneity was decreased or removed after exclusion of three studies: A vs G: Ph=0.086, AA vs GG: Ph=0.283, AG vs GG: Ph=0.315, AA+AG vs GG: Ph=0.259, and AA vs AG+GG: Ph=0.409. Two studies [20,33] were the possible sources of heterogeneity of rs10065172, when excluding, the heterogeneity was removed. (T vs C: Ph=0.596, TT vs CC: Ph=0.930, TC vs CC: Ph=0.677, TT+TC vs CC: Ph=0.727, TT vs TC+CC: Ph=0.810) In the cumulative meta-analysis, the pooled ORs tended to be stable and the associations tended toward significant with accumulation of more data over time between rs13361189, rs4958847 or rs10065172 polymorphism and CD risk. (Figure 5) However, Figure S3 presented that the associations remained non-significant with accumulation of more data over time in rs13361189 or rs4958847 variant and risk of UC.
Figure 5

Cumulative meta-analysis: pooled OR with the corresponding 95% CI at the end of each year information step is shown for IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and risk of CD (dominant model).

Publication bias

Funnel plots and Egger’s test were performed to assess publication bias. The shapes of the funnel plots did not reveal evidence of obvious asymmetry in all comparison models. Then, the Egger’s test was used to provide statistical evidence of funnel plot symmetry. Egger’s test did not show any evidence of publication bias of rs13361189 variant (P=0.237 for CC+CT vs TT in CD, P=0.631 for CC+CT vs TT in UC), rs4958847 variant (P=0.278 for AA+AG vs GG in CD, P=0.108 for AA+AG vs GG in UC), or rs10065172 variant (P=0.479 for TT+TC vs CC in CD). Figure S4 and Figure S5 showed the funnel plots of dominant models in the three IRGM SNPs.

Discussion

IRGM gene, located on chromosome 5q33.1, plays an important role in autophagy. Autophagy has a central function in physiological and pathological processes, involving in innate and adaptive immunity by delivering intracellular pathogens and other antigens. Singh et al demonstrated that IRGM can induce autophagy to eliminate intracellular mycobacterium tuberculosis [41]. Moreover, IRGM 1 -deficient mice have a reduced defense against intracellular pathogens such as Toxoplasma gondii and Listeria monocytogenes [42]. The presence of bacterial flora is essential for IBD formation in animal models [43]. In addition, autophagy plays an important role in the elimination of apoptotic bodies, and the failure of which might contribute to persistent inflammation in CD [44]. In the recent GWAS meta-analysis, Frank provided strong evidence for the association between IRGM rs7714584 and the risk of IBD (P<10-8, meeting genome-wide significance). Parkes et al [18] found two immediately flanking IRGM variants (rs13361189 and rs4958847) associated with CD in two different British cohorts. Thus, IRGM may appear to be a good candidate for IBD. However, the results of associations between three IRGM variants (rs13361189, rs4958847 and rs10065172) and risk of IBD were contradictory. Therefore, we saw the need to perform pooled analyses with larger sample size by summarizing previous case-control studies in order to understand the association between IRGM variants and IBD risk better. Our meta-analysis showed significant susceptibility of CD from rs13361189 in the overall population in all genetic contrasts. When stratified by ethnicity, a significant association with rs13361189 was observed in European population, but not in Asians. Similar results were also found between the rs4958847 or rs10065172 variant and risk of CD in overall and European population. It is widely accepted that genetic markers in predisposition to IBD vary across ethnic groups. For instance, nucleotide oligomerization domain 2 (NOD2) polymorphisms have been strongly association with CD in Europeans [45,46], but not in Asian population [47-49]. These results suggested that rs13361189 and rs4958847 variants might be ethnic population-specific risk factors for CD. However, the lack of association in the Asian population from this study might not be very conclusive owing to the relatively small number of Asian populations used in the analysis (only 2 studies for rs4955847 and 3 studies for rs13361189 in Asian population). Therefore, further studies in Asian populations with larger sample sizes might need to be performed to clarify possible roles of IRGM polymorphisms in CD. Since these SNPs are close to each other, we used 1000 Genomes Pilot sequence data to identify whether these SNPs were in linkage disequilibrium (LD) (r2>0.8). The results showed that rs13361189 was in perfect LD with 2 other IRGM SNPs (rs10065172 and rs1000113, r2=1.000) in Europeans. However, rs4958847 was not in LD with 3 other IRGM SNPs (rs13361189, rs10065172 and rs1000113, r2=0.304). Overall, no significant association between rs13361189 or rs4958847variant and susceptibility to UC was found in this meta-analysis in any genetic model. To date, there was lack of association of these two SNPs with UC in all the individual studies. Recently, twin studies and familial clustering of cases suggested that genetic factors were likely to play a more prominent role in CD than in UC [3]. This observation was also supported by the finding that both NOD2 and ATG16L1 were associated with CD, but not with UC [50,51]. Heterogeneity was significant for the most comparisons of rs13361189 polymorphism in overall population. To identify the source of heterogeneity, meta-regression and subgroup analysis were carried out. We found that ethnicity was identified as a potential source of between-study heterogeneity. Meta-regression indicated that ethnicity could explain 41.37% of τ2. Moreover, the heterogeneity was remarkably decreased among Asian and European population, (CC vs TT: P=0.763, P=0.336, respectively), which may be attributed that IBD is a complex disease and different genetic backgrounds or different environments existed among different ethnicities. Moreover, the sample size could explain 63.28% of τ2 under dominant model. In addition, the pooled OR did not change in the sensitivity analysis by excluding studies departed from HWE. Our meta-analysis significantly increased statistical power by pooling data from different studies, while several limitations should be considered in the present meta-analysis. First, only 2 and 3 studies were performed in Asians for rs4955847 and rs13361189 variants, respectively. Therefore validation of association is required in other population. Second, significant heterogeneity between studies was detected in the current meta-analysis, whereas difference in ethnicity was identified as potential sources of heterogeneity. Third, gene–environment and gene-gene interactions were not analyzed because of insufficient data. In conclusion, despite these limitations, our meta-analysis still yields statistically significant results. The present data synthesis indicated that rs13361189, rs4958847 and rs10065172 were considered to be risk factors of CD in Europeans but not of UC. In addition, subgroups analysis suggested that this increased risk may be ethno-specific. Further studies in other ethnic groups (e.g. Asians and Africans) are needed to clarify possible roles of IRGM polymorphisms in CD or UC. To identify the exact role of IRGM polymorphisms in the pathogenesis of CD, more studies such as animal disease modeling are of great importance. PRISMA checklist. (DOC) Click here for additional data file. OR estimates with the corresponding 95% CI for the associations between IRGM polymorphisms ((A) rs13361189 and (B) rs4958847) and the risk of UC (dominate model). (TIF) Click here for additional data file. Sensitivity analysis on the associations between IRGM polymorphisms ((A) rs13361189 and (B) rs4958847) and UC risk (dominate model). (TIF) Click here for additional data file. Cumulative meta-analysis: pooled OR with the corresponding 95% CI at the end of each year information step is shown for IRGM polymorphisms ((A) rs13361189 and (B) rs4958847) and risk of UC (dominate model). (TIF) Click here for additional data file. Funnel plots of the association between IRGM polymorphisms ((A) rs13361189, (B) rs4958847, and (C) rs10065172) and CD risk (dominant model). (TIF) Click here for additional data file. Funnel plots of the association between IRGM polymorphisms ((A) rs13361189 and (B) rs4958847) and UC risk (dominate model). (TIF) Click here for additional data file.
  49 in total

1.  Autophagy gene-dependent clearance of apoptotic cells during embryonic development.

Authors:  Xueping Qu; Zhongju Zou; Qihua Sun; Kate Luby-Phelps; Pengfei Cheng; Robert N Hogan; Christopher Gilpin; Beth Levine
Journal:  Cell       Date:  2007-03-09       Impact factor: 41.582

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

4.  Human IRGM induces autophagy to eliminate intracellular mycobacteria.

Authors:  Sudha B Singh; Alexander S Davis; Gregory A Taylor; Vojo Deretic
Journal:  Science       Date:  2006-08-03       Impact factor: 47.728

5.  CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: an association study and pooled analysis.

Authors:  L E Oostenbrug; I M Nolte; E Oosterom; G van der Steege; G J te Meerman; H M van Dullemen; J P H Drenth; D J de Jong; K van der Linde; P L M Jansen; J H Kleibeuker
Journal:  Dig Liver Dis       Date:  2006-08-21       Impact factor: 4.088

6.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

7.  Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease.

Authors:  Keiko Yamazaki; Masakazu Takazoe; Torao Tanaka; Toshiki Kazumori; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

8.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  Phenotype-genotype profiles in Crohn's disease predicted by genetic markers in autophagy-related genes (GOIA study II).

Authors:  Cecília Durães; José C Machado; Francisco Portela; Susana Rodrigues; Paula Lago; Marília Cravo; Paula Ministro; Margarida Marques; Isabelle Cremers; João Freitas; José Cotter; Lurdes Tavares; Leopoldo Matos; Isabel Medeiros; Rui Sousa; Jaime Ramos; João Deus; Paulo Caldeira; Cristina Chagas; Maria A Duarte; Raquel Gonçalves; Rui Loureiro; Luísa Barros; Isabel Bastos; Eugénia Cancela; Mário C Moraes; Maria J Moreira; Ana I Vieira; Fernando Magro
Journal:  Inflamm Bowel Dis       Date:  2013-02       Impact factor: 5.325

10.  Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility.

Authors:  Miles Parkes; Jeffrey C Barrett; Natalie J Prescott; Mark Tremelling; Carl A Anderson; Sheila A Fisher; Roland G Roberts; Elaine R Nimmo; Fraser R Cummings; Dianne Soars; Hazel Drummond; Charlie W Lees; Saud A Khawaja; Richard Bagnall; Denis A Burke; Catherine E Todhunter; Tariq Ahmad; Clive M Onnie; Wendy McArdle; David Strachan; Graeme Bethel; Claire Bryan; Cathryn M Lewis; Panos Deloukas; Alastair Forbes; Jeremy Sanderson; Derek P Jewell; Jack Satsangi; John C Mansfield; Lon Cardon; Christopher G Mathew
Journal:  Nat Genet       Date:  2007-06-06       Impact factor: 38.330

View more
  14 in total

Review 1.  Association between NCF4 rs4821544T/C polymorphism and inflammatory bowel disease risk in Caucasian: a meta-analysis.

Authors:  Peng-Bo Wu; Jin-Fen Dai; Qian Wang; Guo Zhang; Shi-Yun Tan; Ming Li; Hui-Lan Ye
Journal:  Inflamm Res       Date:  2015-08-20       Impact factor: 4.575

Review 2.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

3.  Expression of Beclin1 in the colonic mucosa tissues of patients with ulcerative colitis.

Authors:  Xiaoqian Hao; Bin Yang; Xingshan Liu; Huixiang Yang; Xishuang Liu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 4.  ATG16L1: A multifunctional susceptibility factor in Crohn disease.

Authors:  Mohammad Salem; Mette Ammitzboell; Kris Nys; Jakob Benedict Seidelin; Ole Haagen Nielsen
Journal:  Autophagy       Date:  2015-04-03       Impact factor: 16.016

5.  Autophagy-related IRGM genes confer susceptibility to ankylosing spondylitis in a Chinese female population: a case-control study.

Authors:  Q Xia; M Wang; X Yang; X Li; X Zhang; S Xu; Z Shuai; J Xu; D Fan; C Ding; F Pan
Journal:  Genes Immun       Date:  2016-12-29       Impact factor: 2.676

6.  CUBAP: an interactive web portal for analyzing codon usage biases across populations.

Authors:  Matthew W Hodgman; Justin B Miller; Taylor E Meurs; John S K Kauwe
Journal:  Nucleic Acids Res       Date:  2020-11-04       Impact factor: 16.971

7.  NOD2 induces autophagy to control AIEC bacteria infectiveness in intestinal epithelial cells.

Authors:  Anna Negroni; Eleonora Colantoni; Roberta Vitali; Francesca Palone; Maria Pierdomenico; Manuela Costanzo; Vincenzo Cesi; Salvatore Cucchiara; Laura Stronati
Journal:  Inflamm Res       Date:  2016-06-22       Impact factor: 4.575

Review 8.  Autophagy dysfunction in autoinflammatory diseases.

Authors:  Yichao Hua; Min Shen; Christine McDonald; Qingping Yao
Journal:  J Autoimmun       Date:  2017-11-03       Impact factor: 7.094

Review 9.  Manipulating autophagic processes in autoimmune diseases: a special focus on modulating chaperone-mediated autophagy, an emerging therapeutic target.

Authors:  Fengjuan Wang; Sylviane Muller
Journal:  Front Immunol       Date:  2015-05-19       Impact factor: 7.561

10.  Network Analysis of Human Genes Influencing Susceptibility to Mycobacterial Infections.

Authors:  Ettie M Lipner; Benjamin J Garcia; Michael Strong
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.